With a growing emphasis on research and development, collaborations, and strategic initiatives, the liver cancer sector is poised for significant expansion and holds the potential to address the unmet medical needs of patients worldwide. Ongoing efforts in disease awareness, early diagnosis, and the development of targeted therapies contribute to the optimistic outlook for the liver cancer market’s evolution in the foreseeable future.
DelveInsight’s “Liver Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Liver Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Liver Cancer drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Liver Cancer treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Liver Cancer: An Overview
Liver cancer, originating in the liver, ranks as the sixth most frequently diagnosed cancer globally and stands as the third leading cause of cancer-related mortality. Primary liver cancer primarily manifests in two main histological subtypes, namely Hepatocellular Carcinoma (HCC) and Intrahepatic Cholangiocarcinoma (iCCA). These subtypes exhibit distinctions in their origins, causes, and epidemiological patterns. Understanding the nuances of each subtype is crucial for devising targeted and effective diagnostic and therapeutic strategies.
Globally, the main risk factors for HCC are infection with hepatitis B or hepatitis C viruses. HCC can also be caused by heavy alcohol use, obesity, diabetes, and ingestion of aflatoxins. iCCA develops in the bile ducts within the liver. Risk factors for iCCA include primary sclerosing cholangitis, Caroli’s disease, and hepatolithiasis.
Treatment for liver cancer depends on the stage of the condition. If diagnosed early, it may be possible to remove the cancer completely. Treatment options in the early stages of liver cancer include surgical resection, liver transplant, and microwave or radiofrequency ablation.
Only a small proportion of liver cancers are diagnosed at a stage where these treatments are suitable. Most people are diagnosed when the cancer has spread too far to be removed or destroyed. In these cases, treatments such as chemotherapy will be used to slow down the spread of the cancer and relieve symptoms such as pain and discomfort.
Liver Cancer can now be treated with immunotherapy. Some of the approved drugs for liver cancer include atezolizumab and bevacizumab, lenvatinib, and sorafenib.
Liver Cancer Market Key Facts
-
According to the Global Cancer Observatory, in Japan, the ASR incident rate of liver cancer is 10.4/100,000 which is estimated to be around 45,660 new cases diagnosed in 2020 and the ASR mortality rate of liver cancer is 4.8/100,000 which is estimated to be around 28,155 number of deaths in 2020.
-
According to a study done by Siegel et al. 2020, on liver cancer rates used by the National Cancer Institute, there were 42,810 new cases of liver cancer in the United States of America in 2020. Of this number, 30,170 were males and 12,640 were females.
-
According to the latest WHO data published in 2020 Liver Cancer Deaths in Germany reached 8,057 or 1.15% of total deaths.
-
Some of the key players, such as CStone Pharmaceuticals, SOTIO Biotech, Akeso Biopharma, among others, are actively working to develop new therapies for the treatment of Liver Cancer. The emerging therapies hold the potential to transform the treatment scenario in the upcoming years.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Liver Cancer pipeline therapies. It also thoroughly assesses the Liver Cancer market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Liver Cancer drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Liver Cancer Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Liver Cancer epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Liver Cancer epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Liver Cancer Epidemiology, Segmented as –
-
Incident Cases of Liver Cancer
-
Gender-specific Diagnosed Incidence of Liver Cancer
-
Stage-specific Diagnosed Incidence of Liver Cancer
-
Treated cases of Liver Cancer
Liver Cancer Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Liver Cancer market or expected to be launched during the study period. The analysis covers the Liver Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Liver Cancer drugs based on their sale and market share.
The report also covers the Liver Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Liver Cancer companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Liver Cancer Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/liver-cancer-market
Liver Cancer Therapeutics Analysis
Many treatment options are used for liver cancer, including surgery, radiation therapy, and immunotherapy. The appropriate option may depend on how much liver damage has been caused by cancer or other conditions, and whether the cancer has spread elsewhere in the body, among other factors. Treatment options for liver cancer include surgery, ablation, embolization therapy, radiation therapy, immunotherapy, chemotherapy, targeted drug therapy, clinical trials, and gastroenterology procedures.
There are currently several FDA-approved immunotherapy options for liver cancer. Several other immunotherapies are currently being tested in clinical trials, including oncolytic viruses and adoptive cell therapy. The therapy market also includes Bevacizumab (AVASTIN) a targeted antibody that targets the VEGF-A pathway; approved, in combination with atezolizumab, as a first-line treatment for subsets of patients with advanced liver cancer.
Several major pharma and biotech companies are developing therapies for Liver Cancer. Currently, Polaris Group. Is leading the therapeutics market with its Liver Cancer drug candidates in the most advanced stage of clinical development.
Liver Cancer Companies Actively Working in the Therapeutics Market Include
Some of the key companies in the Liver Cancer Marekt include Shanghai Henlius Biotech, Boehringer Ingelheim, Bristol-Myers Squibb, Jiangsu Hengrui Medicine, Glaxo SmithKline, ZAI Lab, Beijing Immunochina Medical Science and Technology, MiNA Therapeutics, Abbisko Therapeutics, Medivir AB, Teclison, Genoscience, Eureka Therapeutics, Celsion Corporation, H3 Biomedicine, TriSalus Life Sciences, Celldex Therapeutics, Takeda, Megapro Biomedical Company, Polaris Group, and many others.
Emerging and Marketed Liver Cancer Therapies Covered in the Report Include:
-
SRF388: Surface Oncology
-
MTL-CEBPA: MiNA Therapeutics
-
APX3330: Ocuphire Pharma
-
Fostroxacitabine bralpamide: Medivir
-
CDX-527: Celldex Therapeutics
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/liver-cancer-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Liver Cancer Competitive Intelligence Analysis
4. Liver Cancer Market Overview at a Glance
5. Liver Cancer Disease Background and Overview
6. Liver Cancer Patient Journey
7. Liver Cancer Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Liver Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Liver Cancer Unmet Needs
10. Key Endpoints of Liver Cancer Treatment
11. Liver Cancer Marketed Therapies
12. Liver Cancer Emerging Drugs and Latest Therapeutic Advances
13. Liver Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Liver Cancer Market Outlook (In US, EU5, and Japan)
16. Liver Cancer Companies Active in the Market
17. Liver Cancer Access and Reimbursement Overview
18. KOL Views on the Liver Cancer Market
19. Liver Cancer Market Drivers
20. Liver Cancer Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/liver-cancer-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Vulvar Squamous Cell Carcinoma Market
“Vulvar Squamous Cell Carcinoma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Vulvar Squamous Cell Carcinoma market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Vulvar Squamous Cell Carcinoma market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research